Synjardy Tablet, Extended Release
Product Images NDC 0597-0290

HCI stands for Human-Computer Interaction. It is a field of study that focuses on the design, evaluation, and implementation of interactive computing systems for human use. HCI aims to create systems that are easy to use, efficient, and satisfying for the user. This field draws upon disciplines such as computer science, psychology, design, and engineering to create technology that is accessible and useful for people.*

This text seems to be a list of drugs and their dosages, including antidiabetic drugs, oral contraceptives, and others. There are also measurements and ratios listed, but without context or further information, it is not possible to determine their significance.*

This is a table showing the mean change from baseline of HbA1c (%) for two medications, Glimepiride + Metformin and Empaglifiozin 25 mg + Metformin. The table lists the mean change values for four different levels of HbA1c and the sample sizes (N) for each medication group. The mean change values are adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*

The text appears to depict a clinical study showing the percentage of patients who experienced an event (not specified) over the course of several months. The study appears to have included two groups: a Placebo group and a group that received Empaglifiozin. However, no further details or context are provided.*

This text appears to be a table or chart of some sort, listing the number of patients with an event (perhaps a medical issue) over time, separated by whether they were given a placebo or a medication called Empaglifiozin. Without more context, it is difficult to provide a more specific description.*

Each tablet of Synjardy XR contains 10mg of empagliflozin and 1000mg of metformin hydrochloride for treatment purposes. The package insert should be consulted for dosage as tablets are not to be split, crushed, dissolved or chewed. The product should be kept within 20°C - 25°C (68°F to 7 excursions permitted o 15°C to 30° (59°F to 86°P) and must be kept out of reach of children. Marketed by Boshingrngelnim 3 Pharmaceutcal I idgened, CT0G877 USA, and Gy USA LLE Indinapols, N 66285 USA. This medication should be used with a medication guide.*

This is a medication called Synjardy XR, which contains 5mg of empagliflozin and 1000mg of metformin hydrochloride in each extended-release tablet. The dosage is to be determined by the package insert and the tablets should not be split, crushed or chewed. The medication should be stored tightly in a container at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The medication is licensed by Bochringer Ingelheim (BI) International GmbH and is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT, and Lilly USA, LLC in Indianapolis.*

Each extended-release tablet contains 25mg of empaghflozin and 1000mg of metformin hydrochloride. The dosage information is available in the package insert. The tablets must be stored at a temperature of 20°C to 25°C and should not be crushed, chewed, or dissolved. The product must be kept out of reach of children. This is a medication marketed by Boehringer Ingetheim. The text seems to be associated with a product called "Synjardy" which is used for treatment purposes.*

This is a medication called Synjardy XR, which is a combination of empagliflozin and metformin hydrochloride. Synjardy XR is an extended-release tablet that contains 12.5 mg of empagliflozin and 1000 mg of metformin hydrochloride. It is not recommended to split, crush, dissolve, or chew the tablets. The tablets should be stored at 20°C to 25°C (68°F to 77°F) and dispensed in a tight container as defined in the USP. This medication is licensed from Boehringer Ingelheim (BI) International GmbH and is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT and Lilly Ush, LLC in Indianapolis, IN. Dosage information can be found in the package insert and the medication should be kept away from children.*